Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salidroside is a phenylethanoid glycoside and the primary active compound found in Rhodiola rosea (commonly known as golden root or 红景天). It is a glucoside of tyrosol. Salidroside has been studied for its broad spectrum of pharmacological activities including antioxidant, anti-inflammatory, neuroprotective, anti-fatigue, anti-aging effects and potential antitumor properties. Mechanistically it modulates multiple signaling pathways such as PI3K/Akt/mTOR and JAK2/STAT3 to exert cytoprotective effects against oxidative stress and inflammation. It also inhibits pro-inflammatory cytokines via NF-κB/MAPK pathways and promotes apoptosis in cancer cells by regulating proteins like Bax/Bcl-2/caspases. Preclinical studies suggest benefits in metabolic disorders (e.g., improving glucose homeostasis), cardiovascular protection under hypoxic conditions, neuroprotection (including cognitive improvement at high altitude), and as an adjuvant to sensitize tumor cells to chemo/radiotherapy by reducing HIF-1α expression[2][6][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salidroside.